Replies to post #10795 on Titan Pharmaceuticals Inc (TTNP)

[F1ash]

Thanks for the informative insights.

The end of the year is swiftly approaching, so I am looking forward to the upcoming announcement. It seems to me that they should be able to include the other drug in their repertoire if they so desired. Are you aware of the comparative preference rates between the two drugs?

[KMBJN]

Neuroderm is developing an apomorphine dopamine agonist continuous delivery system that may be competing with our ropinirole dopamine agonist implant.

http://finance.yahoo.com/news/neuroderm-announces-top-line-results-120000884.html

Both offer continuous delivery of a dopamine agonist. Right now Neuroderm only has subcutaneous pump type delivery of their levodopa formulation and now their apomorphine drug. Soon they will have a disposable patch-pump for administration, better than the belt worn pump, IMO.

Previous dopamine agonist daily skin patch Neupro (rotigotine) didn't go well due to manufacturing issues, recalled in 2008, and now back again doing pretty well for UCB - with 216M Euros in sales in 2015.